A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Ascrinvacumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 10 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.